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Introduction
Since the mid-1980s, preventing HIV transmissionamong people who inject drugs (PWIDs) hasbeen one of the cornerstones of the UK’s response
to HIV. The early comprehensive implementation of
harm reduction, particularly needle and syringe
programmes, has been widely acknowledged as key
to a low prevalence of HIV among PWIDs in the UK.
However, this harm-reduction strategy was developed
to avert an HIV epidemic among people injecting
heroin [1] and while the prevalence in this population
remains low [2,3], it is clear that there are now
emerging populations of PWIDs with different patterns
of drug use and risks [4,5]. This article discusses one
of these: anabolic steroid use in the context of HIV,
and highlights the potential for the nursing profession
to reduce HIV-transmission risk, and to improve the
health of this diverse and vulnerable population
through the use of existing knowledge and expertise.
Anabolic steroids
Anabolic steroids (AS) are one of a range of
enhancement substances known as image and
performance enhancing drugs (IPEDs) that also
includes peptide hormones, growth hormones and
other drugs used to modify appearance. Globally,
lifetime prevalence of AS has been estimated at 3.3%
[6] and evidence indicates an increase in use over
the past 20 years, with a greater number of people
injecting AS presenting at needle and syringe
programmes in Australia [7] and the UK [8,9]. In the
UK, recent evidence from a national survey of people
using IPEDs suggests a heterogeneous population
with a range of drug-use behaviours, risks and
vulnerabilities [10] and the use of these substances
present a number of challenges in relation to
healthcare. This article discusses AS in the context of
HIV, and highlights the potential for the nursing
profession to reduce the risk of HIV transmission and
improve the health of this population of people using
drugs.
The majority of people using AS inject their drugs
[10,11] and are, therefore, at risk of harms associated
with injecting such as injection site injuries, bacterial
infections and blood-borne viruses (BBV) [12]. AS are
only injected subcutaneously and intramuscularly
whereas psychoactive drugs like heroin are most
commonly injected intravenously and this results in
different patterns of injection-related risks. Additionally,
people using these drugs face a range of risks
specifically associated with AS use. There is a growing
evidence base in relation to the acute and chronic
physical and psychological adverse consequences
associated with AS use [13], and adverse effects [12],
which many seek to self-manage through additional
substance use. Complex polypharmacy within IPED
use [14], characterised by dosages beyond any
therapeutic range and an illicit market in which the
contents and purity can never be guaranteed, has
long been established [15].
It is recognised that the population using AS is diverse
with a range of different needs and vulnerabilities.
A recent attempt to demonstrate this suggests that
people using AS may be categorised under four
‘typologies’ [16]. For example, the ‘YOLO’ (You Only
Live Once) type was characterised by experimentation
and risk-taking, including use of recreational drugs
and alcohol, and by little concern for health harms.
Use of illicit substances, particularly cocaine [5,14],
and high levels of alcohol consumption among a
subset of this population [10] increases the risks
associated with both AS and psychoactive substances,
and may be associated with risky sexual behaviours.
Alternatively, it was hypothesised that the ‘Athlete’
type was characterised by combining different AS
and thus risking their health to maximise the chances
of competitive success [16]. Within different groups
of people using AS, therefore, differences in health
risks are likely to exist and further research is required
to increase an understanding of how health services
can identify and respond to these risks.
HIV among those using AS
There is scarce research focusing on AS in comparison
to the body of evidence examining the prevalence
and prevention of BBV among injectors of
psychoactive drugs [17,18]. Historically, case reports
of HIV among people using AS have been very rare
[19–21] and the bio-behavioural surveillance of PWID
had not detected HIV among this population [22].
However, more recent evidence points to HIV among
those using AS emerging as a public health concern.
Published in 2013, the largest study yet of BBV among
those using anabolic steroids and associated drugs,
found that out of the 395 men recruited, 1.5% had
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been infected with HIV, 9% had antibodies to hepatitis
B core antigen (anti-HBc) and 5% to hepatitis C
(anti-HCV) [5]. Analysis of data from this study, a
subsequent targeted survey and the limited historical
data available, demonstrated that BBV infections have
become established among this population, and for
HIV the prevalence is now similar to that of those
injecting psychoactive drugs such as heroin [4].
Route(s), of HIV infection among this population,
however, remain unclear. Although perhaps unlikely,
amongst recent studies examining HIV prevalence,
the use of AS may be related to the past use of these
drugs as part of a medication regimen in relation to
HIV treatment. Research into the behaviours of people
who use AS highlights the possibility of transmission
via the sharing and reuse of injection equipment, and
through sexual activity (Table 1). While less commonly
reported than in those who inject psychoactive drugs,
the sharing of injecting equipment among people
using AS has been noted in several UK studies
[7,23,24], and surveys have also found this population
to be highly sexually active with low rates of condom
use [5,25]. It has been suggested that the risk of BBV
infection through injection may be reduced when
compared to that associated with the injection of
psychoactive drugs [11,26], possibly due to differences
in injection practices, for example, less frequent
injection [27] or ‘off cycle’ periods [12].
The sexual behaviours of those who use AS appear
likely to increase the risk of HIV transmission, with
many reporting high numbers of sexual partners as
well as low rates of condom use [5,22,23,25].
Additionally, of those using AS, HIV is significantly
more common among men who have sex with men
(MSM) [4,29] reflecting the higher prevalence more
generally in this group. High levels of sexual activity
in groups using AS may come as little surprise; for
example, in addition to muscular enhancement,
sporting or occupational reasons, a reported
motivation for AS use is to increase attractiveness in
an often young male population [30]. Furthermore,
use of AS is associated with sports participation or
activities to increase a healthy appearance [30].
Further research into the transmission of BBV among
those who use AS is required, but it is clear that
healthcare must address this risk by not just improving
injection practices but also addressing sexual activities
so as to reduce the risk of BBV among AS users, as
well as in the wider population. Other potential harms
associated with risky sexual activity particularly
among young people and MSM, such as the spread
of sexually transmitted infections and unwanted
pregnancies, must also be considered.
The role of healthcare services
in responding to the risk of HIV
and health harms
There is increasing recognition of the vulnerabilities
and needs of people who use AS reflected in calls
for the provision of specialist services to cater for the
specific needs of this group [3]. However, it remains
important to ensure that people who use AS
presenting at generic healthcare services receive
suitable healthcare. Risks associated with HIV and
other health harms may be confounded by reluctance
in this population to engage with healthcare providers.
In the UK, research indicates that the uptake of testing
for BBV among people using AS is low with under a
half ever being tested [5,10], suggesting that many
infections may go undiagnosed. Increasing awareness
among health professionals about AS-related risks and
harms, including HIV and other infections, and their
adverse effects will provide opportunities to improve
the health of a population who may not be aware
of the risks and the appropriate healthcare services.
Seeking healthcare in response to adverse effects
associated with substance use in this population has
been reported to be infrequent [10,27], although, these
effects may have been minor harms and treatment
may be more likely sought for more serious harms
[31]. Further research is required to better understand
facilitators and barriers to the use of appropriate
healthcare services by this population. Perceptions
of masculinity have long been linked with fewer
help-seeking behaviours and lower use of healthcare
services [32,33] particularly among younger men [34].
The uptake of healthcare services may be seen as
a sign of weakness in males who participate in
health-promoting behaviours such as physical activity
and a healthy diet [35]. For individuals using
substances to enhance muscularity and who are
frequently embedded within gym and sporting
culture, these issues of masculine identity and male
roles are likely to be particularly relevant [36].
Table 1: Blood-borne virus (BBV) prevalence and risk behaviours among people injecting IPEDs, England and Wales: 2012–2015
BBV or risk behaviour Proportion of total surveyed*
HIV (n=603) 1.2%
Current or past hepatitis B (n=603) 2.7%
Current or past hepatitis C (n=603) 4.5%
Ever shared a needle, syringe or vial (n=586) 13%
Always used condoms past year, among those with two or more sexual partners (n=239) 15%
*Combined data from the 2012–2013 and 2014–2015 surveys. Source: Public Health England [28].
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Furthermore, people using AS may perceive that
health professionals lack the knowledge and skills to
address the needs related to their substance use [37]
and this may reduce engagement with healthcare
services, including both drug services and primary
care. Individuals who use AS may have strong beliefs
about the differences between their own substance
use and that of those who use and inject psychoactive
drugs [38]. Where there are concerns about how the
use of AS will be perceived and understood, people
using AS may be disinclined to either access
healthcare services or disclose their substance use
when they do. Nurses and other health professionals
encountering people using AS in primary or secondary
healthcare settings have the opportunity to offer
advice and information on safer injecting and sexual
health, and to encourage the uptake of testing
services. Nurses and healthcare professionals can
draw on their expertise and skills; delivery of these
interventions requires no in-depth knowledge of AS
or the wider AS culture. However, increasing
awareness and an understanding of the characteristics
and risks of people who use AS will support healthcare
professionals to identify AS use, and to identify
opportunities to deliver interventions. HIV testing
should be offered not only to people using AS
presenting at healthcare services for blood tests or
physiological or psychological treatment, but also if
AS use is suspected during routine healthcare
appointments. In the case of a population that is
reluctant to engage in healthcare services, it is
essential that nurses and other healthcare professionals
capitalise on engagement opportunities while
avoiding stigma and the potential for further barriers
to engagement.
Conclusion
It is clear that among the drug-using populations the
risk of HIV and other BBVs goes beyond the injection
of psychoactive drugs and the stereotypical, media-
fuelled image of a ‘drug injector’. The challenge for
health professionals is to reduce risk behaviours and
in turn, prevent the spread of infections among all
people who use drugs including those who use AS.
Healthcare services must find opportunities to offer
testing and treatment for BBV, as well as advice and
information regarding injecting behaviours and sexual
health to this population. It is proposed that nurses
and other healthcare professionals have the
opportunity to apply their skills and knowledge to
deliver interventions to people using AS, including
HIV testing, and increasing their awareness of AS use
and associated risks will support this.
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Cardiovascular disease and HIV:
answers to the self-assessment quiz
1. Options b, c and d are all potential causes
of cardiovascular diseases including
congenital disorders and arrhythmias
2. The correct answer is c
3. The correct answer is b
4. Answers a and b are correct
5. Answers c and d are true
6. The correct answer is b
7. Correct answers include CAC, IMT, CIMT,
CRP and IL6
8. All of the responses are associated with
advancing age
9. Answers a, b and c apply. Answer d also
probably applies, given the current evidence.
10. Activity in the amygdala area of the brain
increases during times of emotional stress. This
heightens bone marrow activity, which in
turn increases inflammatory responses.
11. The statement is true
12. Statements a and b are true
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